Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine for prevention of postoperative delirium/agitation after esophagectomy
IRCT20190325043107N42Phase 3Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in postoperative delirium (POD) and agitation comparing Dexmedetomidine with Normal saline placebo (2 arms). Primary endpoints: Agitation and Delirium prevention. Started Jan 2024; status: completed.
02
Drugs
dexmedetomidine
03
Conditions
postoperative delirium (POD)agitation
Beyond the preview
Go deeper on IRCT20190325043107N42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190325043107N42.